Breaking News

Isis Earns GSK Milestone

July 16, 2014

Advances ISIS-TTRRx

Isis Pharmaceuticals, Inc. has earned a $1 million milestone payment from GlaxoSmithKline for the advancement of the Phase II/III study of ISIS-TTRRx in familial amyloid polyneuropathy (FAP), a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.
 
To date, Isis has earned $27 million in upfront and milestone payments. Should GSK exercise its option to license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestones, and royalties on sales.
 
The Phase II/III study is designed to support an application for marketing approval of ISIS-TTRRx in FAP. The study will measure the effects of ISIS-TTRRx on neurological dysfunction and quality-of-life. ISIS-TTRRx is designed to inhibit the production of all forms of TTR, and to treat all types of transthyretin-related amyloidosis.

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent